SAN DIEGO, CA--(Marketwire - June 28, 2010) - Medistem Inc. (PINKSHEETS: MEDS). Medistem collaborator Dr. Jorge Paz Rodriquez was invited to give a talk at Del Mar College in Texas by arthritis patient Dusty Durrill. The patient described a profound recovery after treatment with stem cells from his own fat tissue. Mr Durrill underwent a procedure in which a small amount of fat tissue was extracted by liposuction, stem cells where purified, and subsequently injected intravenously.
This procedure has been used successfully to treat thousands of animals suffering from arthritis in the United States (www.vet-stem.com). Use of patient’s own stem cells is currently being performed in the United States (www.regenexx.com). Recently Dr. Paz published a paper describing scientific mechanisms of this treatment in collaboration with scientists from the University of California San Diego, University of Western Ontario, and Medistem Inc (Ichim et al. Autologous stromal vascular fraction cells: A tool for facilitating tolerance in rheumatic disease. Cell Immunol. 2010 Apr 8).
“I had treatment for my arthritis, I was not wheelchair bound but I was getting there... after stem cell treatment my arthritis symptoms disappeared,” stated Mr. Durrill.
More than 200 people attended the lecture including the general public, patients and medical doctors. The lecture was focused on US and European clinical trials supporting the use of adult stem cells in conditions ranging from multiple sclerosis, to heart failure, to diabetes. A video of part of the lecture is available at http://www.kiiitv.com/younews/97165699.html.
Dr. Paz commented, “Mr. Durrill suffered from arthritis for more than ten years with severe pain in both knees and hips. He had difficulty standing and limited mobility. After stem cell therapy he started showing significant reduction in pain. Now about a month after therapy he is pain free and can move around easily.”
Drs. Robert Harman, CEO of Vet-Stem and Thomas Ichim, CEO of Medistem, recently released a video discussing their publication on fat stem cell therapy for arthritis. The video is available at http://www.youtube.com/watch?v=3QQrwtp-KQQ.
About Medistem Inc.
Medistem Inc. is a biotechnology company developing technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company’s lead product, the endometrial regenerative cell (ERC), is a “universal donor” stem cell being developed for critical limb ischemia. A publication describing the support for use of ERC for this condition may be found at http://www.translational-medicine.com/content/pdf/1479-5876-6-45.pdf
Cautionary Statement
This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.
Contact:
Thomas E Ichim
Chief Executive Officer
Medistem Inc.
9255 Towne Centre Drive
Suite 450
San Diego CA 92122
858 349 3617
858 642 0027
www.medisteminc.com
Digg this
Bookmark with del.icio.us
Add to Newsvine
Technorati: 
